A meta-analysis including dose-response relationship between night shift work and the risk of colorectal cancer
Xiao Wang(Qingdao University), Liping Xie(First Affiliated Hospital Zhejiang University), Shuai Meng(Capital Medical University), Alin Ji(Zhejiang Provincial People's Hospital), Yi Zhu(Mayo Clinic in Arizona), Shiqi Li(University of Science and Technology of China), Xiangyi Zheng(Tianjin University), Zhen Liang(Capital Medical University), Jian Wu(Sun Yat-sen University)
Cited by 119
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276